- Home
- BREA vs NLSP Comparison
BREA vs NLSP Comparison
Compare BREA & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- NLSP
- Stock Information
- Founded
- BREA 2022
- NLSP 2015
- Country
- BREA Ireland
- NLSP Switzerland
- Employees
- BREA N/A
- NLSP N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- NLSP Health Care
- Exchange
- BREA Nasdaq
- NLSP Nasdaq
- Market Cap
- BREA 14.8M
- NLSP 12.4M
- IPO Year
- BREA 2023
- NLSP 2021
- Fundamental
- Price
- BREA $6.00
- NLSP $1.99
- Analyst Decision
- BREA
- NLSP
- Analyst Count
- BREA 0
- NLSP 0
- Target Price
- BREA N/A
- NLSP N/A
- AVG Volume (30 Days)
- BREA 5.4K
- NLSP 203.0K
- Earning Date
- BREA 01-01-0001
- NLSP 10-17-2025
- Dividend Yield
- BREA N/A
- NLSP N/A
- EPS Growth
- BREA N/A
- NLSP N/A
- EPS
- BREA N/A
- NLSP N/A
- Revenue
- BREA $2,988,009.00
- NLSP N/A
- Revenue This Year
- BREA N/A
- NLSP N/A
- Revenue Next Year
- BREA N/A
- NLSP N/A
- P/E Ratio
- BREA N/A
- NLSP N/A
- Revenue Growth
- BREA 151.51
- NLSP N/A
- 52 Week Low
- BREA $5.00
- NLSP $1.30
- 52 Week High
- BREA $19.50
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- BREA 42.63
- NLSP 40.19
- Support Level
- BREA $5.71
- NLSP $2.03
- Resistance Level
- BREA $6.56
- NLSP $2.29
- Average True Range (ATR)
- BREA 0.24
- NLSP 0.18
- MACD
- BREA -0.05
- NLSP -0.06
- Stochastic Oscillator
- BREA 27.37
- NLSP 11.92
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.